NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NeuroAge Therapeutics

NeuroAge Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.neuroagetx.com/

Last Round

Pre Seed

Feb 16, 2026

Total Funding Raised

$449,817

Company Overview

NeuroAge Therapeutics is a biotechnology company that operates a platform to assess and reverse brain aging, helping reduce the risk of neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Application

Keywords

brain aging clockAI drug discoverybrain age testdementia risk predictionlongevity medicineAlzheimer's diagnosticslongevity techtherapeutics for neurodegenerationmulti-omics platformAI diagnosticspreclinical drug discoveryblood biomarkersbiohackingcognitive testinggenetic testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeuroAge Therapeutics Comps

Public and private peers based on sector, stage, and business model.

NeuroAge Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

NeuroAge Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedFeb 16, 2026
GrantFeb 1, 2024
AcceleratorNov 1, 2023

Key People

Founding team and executive leadership

Christin Glorioso

CEO and Co-founder

Founding Team

NeuroAge Therapeutics Investors

Notable investors and investment history

NeuroAge Therapeutics investors
InvestorRounds
Propel(x)Pre Seed
Gates VenturesPre Seed
R42 GroupPre Seed
Alzheimer's Drug Discovery FoundationPre Seed, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    Monthly visitors increased 141% MoM, reaching 2.9K.

  • Jun 1, 2025

    Monthly visitors grew 490% MoM, reaching 11.8K.

NeuroAge Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NeuroAge Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NeuroAge Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range19
Year Founded2022
Last FundingFeb 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.